Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD)

Baiba Hedegaard Hansen, Jamal Abed Hanash, Alice Rasmussen, Jørgen Fischer Hansen, Morten Birket-Smith, Baiba Hedegaard Hansen, Jamal Abed Hanash, Alice Rasmussen, Jørgen Fischer Hansen, Morten Birket-Smith

Abstract

Background: The prevalence of depression in patients with acute coronary syndrome, i.e. myocardial infarction and unstable angina, is higher than in the general population. The prevalence of anxiety is higher as well. Both depression and anxiety are associated with poor cardiac outcomes and higher mortality. Comorbid depression in patients with acute coronary syndrome often goes undiagnosed, and it is therefore a challenging task to prevent this risk factor. The study of DEpression in Coronary ARtery Disease (DECARD) is designed to examine if it is possible to prevent depression in patients with acute coronary syndrome.

Methods: Two hundred forty non-depressed patients with acute coronary syndrome are randomized to treatment with either escitalopram or placebo for 1 year. Psychiatric and cardiac assessment of patients is performed to evaluate the possibility of preventing depression. Diagnosis of depression and Hamilton Depression Scale are the primary outcome measures.

Discussion: This is the first study of prevention of depression in patients after acute coronary syndrome with a selective serotonin reuptake inhibitor.

Trial registration: http://www.ClinicalTrials.gov. Identifier: NCT00140257.

Figures

Figure 1
Figure 1
flow chart.

References

    1. Sorensen C, Brandes A, Hendricks O, Thrane J, Friis-Hasche E, Haghfelt T, Bech P. Psychosocial predictors of depression in patients with acute coronary syndrome. Acta Psychiatr Scand. 2005;111:116–124. doi: 10.1111/j.1600-0447.2004.00430.x.
    1. Ellis JJ, Eagle KA, Kline-Rogers EM, Erickson SR. Depressive symptoms and treatment after acute coronary syndrome. Int J Cardiol. 2005;99:443–447. doi: 10.1016/j.ijcard.2004.09.011.
    1. Spijkerman T, de Jonge P, Brink RH van den, Jansen JH, May JF, Crijns HJ, Ormel J. Depression following myocardial infarction: first-ever versus ongoing and recurrent episodes. Gen Hosp Psychiatry. 2005;27:411–417. doi: 10.1016/j.genhosppsych.2005.05.007.
    1. Mallik S, Spertus JA, Reid KJ, Krumholz HM, Rumsfeld JS, Weintraub WS, Agarwal P, Santra M, Bidyasar S, Lichtman JH, Wenger NK, Vaccarino V, PREMIER Registry Investigators Depressive symptoms after acute myocardial infarction: evidence for highest rates in younger women. Arch Intern Med. 2006;166:876–883. doi: 10.1001/archinte.166.8.876.
    1. McGee HM, Doyle F, Conroy RM, De La HD, Shelley E. Impact of briefly-assessed depression on secondary prevention outcomes after acute coronary syndrome: a one-year longitudinal survey. BMC Health Serv Res. 2006;6:9. doi: 10.1186/1472-6963-6-9.
    1. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation. 1995;91:999–1005.
    1. Frasure-Smith N, Lesperance F, Gravel G, Masson A, Juneau M, Talajic M, Bourassa MG. Depression and health-care costs during the first year following myocardial infarction. J Psychosom Res. 2000;48:471–478. doi: 10.1016/S0022-3999(99)00088-4.
    1. Grace SL, Abbey SE, Kapral MK, Fang J, Nolan RP, Stewart DE. Effect of depression on five-year mortality after an acute coronary syndrome. Am J Cardiol. 2005;96:1179–1185. doi: 10.1016/j.amjcard.2005.06.052.
    1. Denollet J, Strik JJ, Lousberg R, Honig A. Recognizing increased risk of depressive comorbidity after myocardial infarction: looking for 4 symptoms of anxiety-depression. Psychother Psychosom. 2006;75:346–352. doi: 10.1159/000095440.
    1. Pedersen SS, Denollet J, Spindler H, Ong AT, Serruys PW, Erdman RA, van Domburg RT. Anxiety enhances the detrimental effect of depressive symptoms on health status following percutaneous coronary intervention. J Psychosom Res. 2006;61:783–789. doi: 10.1016/j.jpsychores.2006.06.009.
    1. Strik JJ, Denollet J, Lousberg R, Honig A. Comparing symptoms of depression and anxiety as predictors of cardiac events and increased health care consumption after myocardial infarction. J Am Coll Cardiol. 2003;42:1801–1807. doi: 10.1016/j.jacc.2003.07.007.
    1. Frasure-Smith N, Lesperance F, Talajic M. The impact of negative emotions on prognosis following myocardial infarction: is it more than depression? Health Psychol. 1995;14:388–398. doi: 10.1037/0278-6133.14.5.388.
    1. Fauerbach JA, Bush DE, Thombs BD, McCann UD, Fogel J, Ziegelstein RC. Depression following acute myocardial infarction: a prospective relationship with ongoing health and function. Psychosomatics. 2005;46:355–361. doi: 10.1176/appi.psy.46.4.355.
    1. van Melle JP, de Jonge P, Ormel J, Crijns HJ, van Veldhuisen DJ, Honig A, Schene AH, Berg MP van den, MIND-IT investigators Relationship between left ventricular dysfunction and depression following myocardial infarction: data from the MIND-IT. Eur Heart J. 2005;26:2650–2656. doi: 10.1093/eurheartj/ehi480.
    1. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, Czajkowski SM, DeBusk R, Hosking J, Jaffe A, Kaufmann PG, Mitchell P, Norman J, Powell LH, Raczynski JM, Schneiderman N, Enhancing Recovery in Coronary Heart Disease Patients Investigators (ENRICHD) Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003;289:3106–3116. doi: 10.1001/jama.289.23.3106.
    1. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT, Jr, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Barton D, Mclvor M, Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288:701–709. doi: 10.1001/jama.288.6.701.
    1. van Melle JP, de Jonge P, Honig A, Schene AH, Kuyper AM, Crijns HJ, Schins A, Tulner D, Berg MP van den, Ormel J, MIND-IT investigators Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry. 2007;190:460–466. doi: 10.1192/bjp.bp.106.028647.
    1. Lesperance F, Frasure-Smith N, Koszycki D, Laliberte MA, Van Zyl LT, Baker B, Swenson JR, Ghatavi K, Abramson BL, Dorian P, Guertin MC, CREATE Investigators Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007;297:367–379. doi: 10.1001/jama.297.4.367.
    1. Thombs BD, de Jonge P, Coyne JC, Whooley MA, Frasure-Smith N, Mitchell AJ, Zuidersma M, Eze-Nliam C, Lima BB, Smith CG, Soderlund K, Ziegelstein RC. Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA. 2008;300:2161–2171. doi: 10.1001/jama.2008.667.
    1. Carney RM, Saunders RD, Freedland KE, Stein P, Rich MW, Jaffe AS. Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol. 1995;76:562–564. doi: 10.1016/S0002-9149(99)80155-6.
    1. Carney RM, Freedland KE, Veith RC, Cryer PE, Skala JA, Lynch T, Jaffe AS. Major depression, heart rate, and plasma norepinephrine in patients with coronary heart disease. Biol Psychiatry. 1999;45:458–463. doi: 10.1016/S0006-3223(98)00049-3.
    1. Carney RM, Freedland KE, Stein PK, Skala JA, Hoffman P, Jaffe AS. Change in heart rate and heart rate variability during treatment for depression in patients with coronary heart disease. Psychosom Med. 2000;62:639–647.
    1. Carney RM, Blumenthal JA, Stein PK, Watkins L, Catellier D, Berkman LF, Czajkowski SM, O'Connor C, Stone PH, Freedland KE. Depression, heart rate variability, and acute myocardial infarction. Circulation. 2001;104:2024–2028. doi: 10.1161/hc4201.097834.
    1. Carney RM, Blumenthal JA, Freedland KE, Stein PK, Howells WB, Berkman LF, Watkins LL, Czajkowski SM, Hayano J, Domitrovich PP, Jaffe AS. Low heart rate variability and the effect of depression on post-myocardial infarction mortality. Arch Intern Med. 2005;165:1486–1491. doi: 10.1001/archinte.165.13.1486.
    1. Davidson J, Watkins L, Owens M, Krulewicz S, Connor K, Carpenter D, Krishnan R, Nemeroff C. Effects of paroxetine and venlafaxine XR on heart rate variability in depression. J Clin Psychopharmacol. 2005;25:480–484. doi: 10.1097/01.jcp.0000177547.28961.03.
    1. Kuijpers PM, Hamulyak K, Strik JJ, Wellens HJ, Honig A. Beta-thromboglobulin and platelet factor 4 levels in post-myocardial infarction patients with major depression. Psychiatry Res. 2002;109:207–210. doi: 10.1016/S0165-1781(02)00017-3.
    1. Laghrissi-Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry. 1997;42:290–295. doi: 10.1016/S0006-3223(96)00345-9.
    1. Serebruany VL, O'Connor CM, Gurbel PA. Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. Am J Cardiol. 2001;87:1398–1400. doi: 10.1016/S0002-9149(01)01562-4.
    1. Serebruany VL, Gurbel PA, O'Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res. 2001;43:453–462. doi: 10.1006/phrs.2001.0817.
    1. Broadley AJ, Korszun A, Jones CJ, Frenneaux MP. Arterial endothelial function is impaired in treated depression. Heart. 2002;88:521–523. doi: 10.1136/heart.88.5.521.
    1. Sherwood A, Hinderliter AL, Watkins LL, Waugh RA, Blumenthal JA. Impaired endothelial function in coronary heart disease patients with depressive symptomatology. J Am Coll Cardiol. 2005;46:656–659. doi: 10.1016/j.jacc.2005.05.041.
    1. Amin AA, Jones AM, Nugent K, Rumsfeld JS, Spertus JA. The prevalence of unrecognized depression in patients with acute coronary syndrome. Am Heart J. 2006;152:928–934. doi: 10.1016/j.ahj.2006.05.006.
    1. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined – a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959–969. doi: 10.1016/S0735-1097(00)00804-4.
    1. Schedules for Clinical Assessment in Neuropsychiatry, Version 21 Århus. 2000.
    1. Spitzer RL, Williams JB, Kroenke K, Linzer M, deGruy FV, III, Hahn SR, Brody D, Johnson JG. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA. 1994;272:1749–1756. doi: 10.1001/jama.272.22.1749.
    1. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62. doi: 10.1136/jnnp.23.1.56.
    1. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50–55.
    1. Guy W. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education and Welfare. 1976. pp. 218–222.
    1. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1–100. doi: 10.1111/j.1600-0447.1987.tb10566.x.
    1. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571.
    1. Olsen LR, Mortensen EL, Bech P. The SCL-90 and SCL-90R versions validated by item response models in a Danish community sample. Acta Psychiatr Scand. 2004;110:225–229. doi: 10.1111/j.1600-0447.2004.00399.x.
    1. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483. doi: 10.1097/00005650-199206000-00002.
    1. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. The ENRICHD investigators. Am Heart J. 2000;139:1–9.
    1. Murdoch D, Keam SJ. Escitalopram: a review of its use in the management of major depressive disorder. Drugs. 2005;65:2379–2404. doi: 10.2165/00003495-200565160-00013.
    1. Bech P O, et al. Scales of Assessment of Diagnosis and Severity of Mental Disorders. Acta Psychiatr Scand Suppl. 1993;87:3–83. doi: 10.1111/j.1600-0447.1993.tb05583.x.
    1. Lesperance F, Frasure-Smith N, Talajic M. Major depression before and after myocardial infarction: its nature and consequences. Psychosom Med. 1996;58:99–110.
    1. Blier P, Keller MB, Pollack MH, Thase ME, Zajecka JM, Dunner DL. Preventing recurrent depression: long-term treatment for major depressive disorder. J Clin Psychiatry. 2007;68:e06.
    1. Lustman PJ, Clouse RE, Nix BD, Freedland KE, Rubin EH, McGill JB, Williams MM, Gelenberg AJ, Ciechanowski PS, Hirsch IB. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:521–529. doi: 10.1001/archpsyc.63.5.521.
    1. Strik JJ, Honig A, Lousberg R, Lousberg AH, Cheriex EC, Tuynman-Qua HG, Kuijpers PM, Wellens HJ, Van Praag HM. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med. 2000;62:783–789.
    1. Rasmussen A, Lunde M, Poulsen DL, Sorensen K, Qvitzau S, Bech P. A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics. 2003;44:216–221. doi: 10.1176/appi.psy.44.3.216.
    1. Wade A, Despiegel N, Heldbo RE. Escitalopram in the long-term treatment of major depressive disorder. Ann Clin Psychiatry. 2006;18:83–89. doi: 10.1080/10401230600614447.
    1. Swenson JR, Doucette S, Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Can J Psychiatry. 2006;51:923–929.
    1. Markovitz JH, Shuster JL, Chitwood WS, May RS, Tolbert LC. Platelet activation in depression and effects of sertraline treatment: An open-label study. Am J Psychiatry. 2000;157:1006–1008. doi: 10.1176/appi.ajp.157.6.1006.
    1. Javors MA, Houston JP, Tekell JL, Brannan SK, Frazer A. Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. Int J Neuropsychopharmacol. 2000;3:229–235. doi: 10.1017/S146114570000198X.
    1. Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, Van Zyl LT, Finkel MS, Krishnan KR, Gaffney M, Harrison W, Califf RM, O'Connor CM, Sertraline AntiDepressant Heart Attack Randomized Trial Study Group Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003;108:939–944. doi: 10.1161/01.CIR.0000085163.21752.0A.
    1. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost. 2004;91:119–128.
    1. Schlienger RG, Fischer LM, Jick H, Meier CR. Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Saf. 2004;27:1157–1165. doi: 10.2165/00002018-200427140-00006.
    1. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003;108:32–36. doi: 10.1161/.
    1. Ziegelstein RC, Meuchel J, Kim TJ, Latif M, Alvarez W, Dasgupta N, Thombs BD. Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes. Am J Med. 2007;120:525–530. doi: 10.1016/j.amjmed.2006.10.026.
    1. Belcher PR, Drake-Holland AJ, Noble MIM. Serotonin Reuptake Inhibitors and Cardiovascular Disease. Vascular Disease Prevention. 2005;2:67–76. doi: 10.2174/1567270052774368.
    1. Meijer WE, Heerdink ER, Nolen WA, Herings RM, Leufkens HG, Egberts AC. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med. 2004;164:2367–2370. doi: 10.1001/archinte.164.21.2367.
    1. de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319:1106–1109.
    1. Wessinger S, Kaplan M, Choi L, Williams M, Lau C, Sharp L, Crowell MD, Keshavarzian A, Jones MP. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther. 2006;23:937–944. doi: 10.1111/j.1365-2036.2006.02859.x.
    1. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003;163:59–64. doi: 10.1001/archinte.163.1.59.
    1. Tata LJ, Fortun PJ, Hubbard RB, Smeeth L, Hawkey CJ, Smith CJ, Whitaker HJ, Farrington CP, Card TR, West J. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther. 2005;22:175–181. doi: 10.1111/j.1365-2036.2005.02543.x.
    1. McFarlane A, Kamath MV, Fallen EL, Malcolm V, Cherian F, Norman G. Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am Heart J. 2001;142:617–623. doi: 10.1067/mhj.2001.116766.
    1. Dickens CM, McGowan L, Percival C, Tomenson B, Cotter L, Heagerty A, Creed FH. Contribution of depression and anxiety to impaired health-related quality of life following first myocardial infarction. Br J Psychiatry. 2006;189:367–372. doi: 10.1192/bjp.bp.105.018234.
    1. Konsensusrapport. Akut koronart syndrom. Retningslinjer for diagnostik og behandling. København, Dansk Cardiologisk Selskab; 2004.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren